 | • レポートコード：D005-00316 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、血液疾患薬＆診断の世界市場を広く調査・分析し、今後の市場展望をまとめております。血液疾患薬＆診断の種類別市場規模（アナライザー、試薬）、用途別市場規模（学術研究機関、ポイントオブケア検査、患者自己検査、バイオ医薬品産業、病院、臨床検査室）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Abbot、Eli Lilly、Beckman Coulter、Pfizer、Biorad、Amgen、Bristol-Myers、Roche、Mindray、Sysmex、Siemens、Horbia、Nihon Kohden ・地域別グローバル市場分析 2015年-2020年 ・血液疾患薬＆診断の北米市場（アメリカ、カナダ、メキシコ） ・血液疾患薬＆診断のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・血液疾患薬＆診断のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・血液疾患薬＆診断の南米市場（ブラジル、アルゼンチン） ・血液疾患薬＆診断の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アナライザー、試薬 ・用途別分析：学術研究機関、ポイントオブケア検査、患者自己検査、バイオ医薬品産業、病院、臨床検査室 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Drugs and Diagnostics for Hematological Disorders market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.1% in the forecast period of 2020 to 2025 and will expected to reach USD 114160 million by 2025, from USD 97320 million in 2019.
The Drugs and Diagnostics for Hematological Disorders market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Drugs and Diagnostics for Hematological Disorders market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs and Diagnostics for Hematological Disorders market has been segmented into:
Analyzers
Reagents
By Application, Drugs and Diagnostics for Hematological Disorders has been segmented into:
Academic and Research Institute
Point of Care Testing
Patient Self-testing
Biopharmaceutical Industries
Hospitals
Clinical Laboratories
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs and Diagnostics for Hematological Disorders market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs and Diagnostics for Hematological Disorders markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs and Diagnostics for Hematological Disorders market.
The report offers in-depth assessment of the growth and other aspects of the Drugs and Diagnostics for Hematological Disorders market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs and Diagnostics for Hematological Disorders Market Share Analysis
Drugs and Diagnostics for Hematological Disorders competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs and Diagnostics for Hematological Disorders sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs and Diagnostics for Hematological Disorders sales, revenue and market share for each player covered in this report.
The major players covered in Drugs and Diagnostics for Hematological Disorders are:
Abbot
Eli Lilly
Beckman Coulter
Pfizer
Biorad
Amgen
Bristol-Myers
Roche
Mindray
Sysmex
Siemens
Horbia
Nihon Kohden
Table of Contents
1 Drugs and Diagnostics for Hematological Disorders Market Overview
1.1 Product Overview and Scope of Drugs and Diagnostics for Hematological Disorders
1.2 Classification of Drugs and Diagnostics for Hematological Disorders by Type
1.2.1 Global Drugs and Diagnostics for Hematological Disorders Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Type in 2019
1.2.3 Analyzers
1.2.4 Reagents
1.3 Global Drugs and Diagnostics for Hematological Disorders Market by Application
1.3.1 Overview: Global Drugs and Diagnostics for Hematological Disorders Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Academic and Research Institute
1.3.3 Point of Care Testing
1.3.4 Patient Self-testing
1.3.5 Biopharmaceutical Industries
1.3.6 Hospitals
1.3.7 Clinical Laboratories
1.4 Global Drugs and Diagnostics for Hematological Disorders Market by Regions
1.4.1 Global Drugs and Diagnostics for Hematological Disorders Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Drugs and Diagnostics for Hematological Disorders (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Drugs and Diagnostics for Hematological Disorders Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Drugs and Diagnostics for Hematological Disorders Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Drugs and Diagnostics for Hematological Disorders Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Drugs and Diagnostics for Hematological Disorders Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Drugs and Diagnostics for Hematological Disorders Status and Prospect (2015-2025)
2 Company Profiles
2.1 Abbot
2.1.1 Abbot Details
2.1.2 Abbot Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Abbot SWOT Analysis
2.1.4 Abbot Product and Services
2.1.5 Abbot Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eli Lilly SWOT Analysis
2.2.4 Eli Lilly Product and Services
2.2.5 Eli Lilly Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.3 Beckman Coulter
2.3.1 Beckman Coulter Details
2.3.2 Beckman Coulter Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Beckman Coulter SWOT Analysis
2.3.4 Beckman Coulter Product and Services
2.3.5 Beckman Coulter Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.5 Biorad
2.5.1 Biorad Details
2.5.2 Biorad Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Biorad SWOT Analysis
2.5.4 Biorad Product and Services
2.5.5 Biorad Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.6 Amgen
2.6.1 Amgen Details
2.6.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Amgen SWOT Analysis
2.6.4 Amgen Product and Services
2.6.5 Amgen Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.7 Bristol-Myers
2.7.1 Bristol-Myers Details
2.7.2 Bristol-Myers Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Bristol-Myers SWOT Analysis
2.7.4 Bristol-Myers Product and Services
2.7.5 Bristol-Myers Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Roche SWOT Analysis
2.8.4 Roche Product and Services
2.8.5 Roche Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.9 Mindray
2.9.1 Mindray Details
2.9.2 Mindray Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Mindray SWOT Analysis
2.9.4 Mindray Product and Services
2.9.5 Mindray Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.10 Sysmex
2.10.1 Sysmex Details
2.10.2 Sysmex Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Sysmex SWOT Analysis
2.10.4 Sysmex Product and Services
2.10.5 Sysmex Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.11 Siemens
2.11.1 Siemens Details
2.11.2 Siemens Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Siemens SWOT Analysis
2.11.4 Siemens Product and Services
2.11.5 Siemens Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.12 Horbia
2.12.1 Horbia Details
2.12.2 Horbia Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Horbia SWOT Analysis
2.12.4 Horbia Product and Services
2.12.5 Horbia Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
2.13 Nihon Kohden
2.13.1 Nihon Kohden Details
2.13.2 Nihon Kohden Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Nihon Kohden SWOT Analysis
2.13.4 Nihon Kohden Product and Services
2.13.5 Nihon Kohden Drugs and Diagnostics for Hematological Disorders Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Drugs and Diagnostics for Hematological Disorders Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Drugs and Diagnostics for Hematological Disorders Players Market Share
3.2.2 Top 10 Drugs and Diagnostics for Hematological Disorders Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Drugs and Diagnostics for Hematological Disorders Revenue and Market Share by Regions
4.2 North America Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
4.3 Europe Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
4.5 South America Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
5 North America Drugs and Diagnostics for Hematological Disorders Revenue by Countries
5.1 North America Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
5.2 USA Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
5.3 Canada Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
5.4 Mexico Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
6 Europe Drugs and Diagnostics for Hematological Disorders Revenue by Countries
6.1 Europe Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
6.2 Germany Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
6.3 UK Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
6.4 France Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
6.5 Russia Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
6.6 Italy Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue by Countries
7.1 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
7.2 China Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
7.3 Japan Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
7.4 Korea Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
7.5 India Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
8 South America Drugs and Diagnostics for Hematological Disorders Revenue by Countries
8.1 South America Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
8.2 Brazil Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
8.3 Argentina Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Drugs and Diagnostics for Hematological Disorders by Countries
9.1 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
9.2 Saudi Arabia Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
9.3 UAE Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
9.4 Egypt Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
9.5 South Africa Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Drugs and Diagnostics for Hematological Disorders Revenue and Market Share by Type (2015-2020)
10.2 Global Drugs and Diagnostics for Hematological Disorders Market Forecast by Type (2019-2024)
10.3 Analyzers Revenue Growth Rate (2015-2025)
10.4 Reagents Revenue Growth Rate (2015-2025)
11 Global Drugs and Diagnostics for Hematological Disorders Market Segment by Application
11.1 Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Application (2015-2020)
11.2 Drugs and Diagnostics for Hematological Disorders Market Forecast by Application (2019-2024)
11.3 Academic and Research Institute Revenue Growth (2015-2020)
11.4 Point of Care Testing Revenue Growth (2015-2020)
11.5 Patient Self-testing Revenue Growth (2015-2020)
11.6 Biopharmaceutical Industries Revenue Growth (2015-2020)
11.7 Hospitals Revenue Growth (2015-2020)
11.8 Clinical Laboratories Revenue Growth (2015-2020)
12 Global Drugs and Diagnostics for Hematological Disorders Market Size Forecast (2021-2025)
12.1 Global Drugs and Diagnostics for Hematological Disorders Market Size Forecast (2021-2025)
12.2 Global Drugs and Diagnostics for Hematological Disorders Market Forecast by Regions (2021-2025)
12.3 North America Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
12.4 Europe Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
12.6 South America Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Drugs and Diagnostics for Hematological Disorders Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs and Diagnostics for Hematological Disorders by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs and Diagnostics for Hematological Disorders Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Abbot Corporate Information, Location and Competitors
Table 6. Abbot Drugs and Diagnostics for Hematological Disorders Major Business
Table 7. Abbot Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 8. Abbot SWOT Analysis
Table 9. Abbot Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 10. Abbot Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Eli Lilly Corporate Information, Location and Competitors
Table 12. Eli Lilly Drugs and Diagnostics for Hematological Disorders Major Business
Table 13. Eli Lilly Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2018-2019)
Table 14. Eli Lilly SWOT Analysis
Table 15. Eli Lilly Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 16. Eli Lilly Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Beckman Coulter Corporate Information, Location and Competitors
Table 18. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Major Business
Table 19. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 20. Beckman Coulter SWOT Analysis
Table 21. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 22. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Pfizer Corporate Information, Location and Competitors
Table 24. Pfizer Drugs and Diagnostics for Hematological Disorders Major Business
Table 25. Pfizer Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 26. Pfizer SWOT Analysis
Table 27. Pfizer Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 28. Pfizer Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Biorad Corporate Information, Location and Competitors
Table 30. Biorad Drugs and Diagnostics for Hematological Disorders Major Business
Table 31. Biorad Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 32. Biorad SWOT Analysis
Table 33. Biorad Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 34. Biorad Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Amgen Corporate Information, Location and Competitors
Table 36. Amgen Drugs and Diagnostics for Hematological Disorders Major Business
Table 37. Amgen Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 38. Amgen SWOT Analysis
Table 39. Amgen Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 40. Amgen Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Bristol-Myers Corporate Information, Location and Competitors
Table 42. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Major Business
Table 43. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 44. Bristol-Myers SWOT Analysis
Table 45. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 46. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Roche Corporate Information, Location and Competitors
Table 48. Roche Drugs and Diagnostics for Hematological Disorders Major Business
Table 49. Roche Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 50. Roche SWOT Analysis
Table 51. Roche Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 52. Roche Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Mindray Corporate Information, Location and Competitors
Table 54. Mindray Drugs and Diagnostics for Hematological Disorders Major Business
Table 55. Mindray Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 56. Mindray SWOT Analysis
Table 57. Mindray Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 58. Mindray Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Sysmex Corporate Information, Location and Competitors
Table 60. Sysmex Drugs and Diagnostics for Hematological Disorders Major Business
Table 61. Sysmex Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 62. Sysmex SWOT Analysis
Table 63. Sysmex Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 64. Sysmex Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Siemens Corporate Information, Location and Competitors
Table 66. Siemens Drugs and Diagnostics for Hematological Disorders Major Business
Table 67. Siemens Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 68. Siemens SWOT Analysis
Table 69. Siemens Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 70. Siemens Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Horbia Corporate Information, Location and Competitors
Table 72. Horbia Drugs and Diagnostics for Hematological Disorders Major Business
Table 73. Horbia Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 74. Horbia SWOT Analysis
Table 75. Horbia Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 76. Horbia Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Nihon Kohden Corporate Information, Location and Competitors
Table 78. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Major Business
Table 79. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Total Revenue (USD Million) (2017-2018)
Table 80. Nihon Kohden SWOT Analysis
Table 81. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Product and Solutions
Table 82. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) by Players (2015-2020)
Table 84. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Players (2015-2020)
Table 85. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) by Regions (2015-2020)
Table 86. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Regions (2015-2020)
Table 87. North America Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
Table 88. North America Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Table 89. Europe Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) by Countries (2015-2020)
Table 90. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) by Countries (2015-2020)
Table 91. South America Drugs and Diagnostics for Hematological Disorders Revenue by Countries (2015-2020)
Table 92. South America Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Table 93. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) by Countries (2015-2020)
Table 94. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Table 95. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) by Type (2015-2020)
Table 96. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Type (2015-2020)
Table 97. Global Drugs and Diagnostics for Hematological Disorders Revenue Forecast by Type (2021-2025)
Table 98. Global Drugs and Diagnostics for Hematological Disorders Revenue by Application (2015-2020)
Table 99. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Application (2015-2020)
Table 100. Global Drugs and Diagnostics for Hematological Disorders Revenue Forecast by Application (2021-2025)
Table 101. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Drugs and Diagnostics for Hematological Disorders Picture
Figure 2. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Type in 2019
Figure 3. Analyzers Picture
Figure 4. Reagents Picture
Figure 5. Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Application in 2019
Figure 6. Academic and Research Institute Picture
Figure 7. Point of Care Testing Picture
Figure 8. Patient Self-testing Picture
Figure 9. Biopharmaceutical Industries Picture
Figure 10. Hospitals Picture
Figure 11. Clinical Laboratories Picture
Figure 12. Global Drugs and Diagnostics for Hematological Disorders Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Drugs and Diagnostics for Hematological Disorders Revenue Market Share in 2019
Figure 21. Global Top 10 Players Drugs and Diagnostics for Hematological Disorders Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Regions (2015-2020)
Figure 25. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Regions in 2018
Figure 26. North America Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 27. Europe Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 29. South America Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 31. North America Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Figure 32. North America Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries in 2019
Figure 33. USA Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 34. Canada Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 36. Europe Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries in 2019
Figure 38. Germany Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 39. UK Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 40. France Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 41. Russia Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 42. Italy Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries in 2019
Figure 45. China Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 46. Japan Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 47. Korea Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 48. India Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 50. South America Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Figure 51. South America Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries in 2019
Figure 52. Brazil Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 57. UAE Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Drugs and Diagnostics for Hematological Disorders Revenue and Growth Rate (2015-2020)
Figure 60. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Type (2015-2020)
Figure 61. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Type in 2019
Figure 62. Global Drugs and Diagnostics for Hematological Disorders Market Share Forecast by Type (2021-2025)
Figure 63. Global Analyzers Revenue Growth Rate (2015-2020)
Figure 64. Global Reagents Revenue Growth Rate (2015-2020)
Figure 65. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Application (2015-2020)
Figure 66. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Application in 2019
Figure 67. Global Drugs and Diagnostics for Hematological Disorders Market Share Forecast by Application (2021-2025)
Figure 68. Global Academic and Research Institute Revenue Growth Rate (2015-2020)
Figure 69. Global Point of Care Testing Revenue Growth Rate (2015-2020)
Figure 70. Global Patient Self-testing Revenue Growth Rate (2015-2020)
Figure 71. Global Biopharmaceutical Industries Revenue Growth Rate (2015-2020)
Figure 72. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 73. Global Clinical Laboratories Revenue Growth Rate (2015-2020)
Figure 74. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Drugs and Diagnostics for Hematological Disorders Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
Figure 78. Europe Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
Figure 80. South America Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Drugs and Diagnostics for Hematological Disorders Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
骨髄増殖性疾患薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Myeloproliferative Disorders Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 1.8% in the forecast period of 2020 to 2025 and will expected to reach USD 7146 million by 2025, from USD 6642.1 million in 2019. The Mye…- 血液がんの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Hematological Cancers market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Hematological Cancers m…
- 薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 6615.9 million by 2025, from…
- 精神疾患治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Mental Illness Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Mental Illness Drugs mar…
- 免疫腫瘍薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Immuno-oncology Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 8.1% in the forecast period of 2020 to 2025 and will expected to reach USD 73080 million by 2025, from USD 53550 million in 2019. The Immuno-oncology …